This Month in Psychopharmacology

THIS MONTH IN
PSYCHOPHARMACOLOGY

Symptoms of Anxiety or Depressive Disorder Among Adults During the COVID-19 Pandemic
April 15, 2021

Rapid monitoring of mental health status and access to care during the COVID-19 pandemic can help accelerate the deployment and evaluation of mental health services. To this end, the Center for Disease Control (CDC) partnered with the...

Continue reading (Members only)

Guidelines For The Use Of Ketamine For Treatment-Resistant Depression
April 12, 2021

An international expert opinion on the use of ketamine for treatment-resistant depression was recently published. Although the various formulations of ketamine have not been compared directly in randomized controlled trials, intranasal esketamine and intravenous ketamine have the strongest evidence of short-term efficacy and safety in patients with ..

Disturbed Sleep and Depression in Children and Youths
April 9, 2021

In a recently published meta-analysis, the relationship between disturbed sleep and depression was examined. A total of 22 studies were included in the study, of which 16 were included in the meta-analysis. Disturbed sleep was...

Continue reading (Members only)

High-Risk Youth Population Are Not Receiving Behavioral Health Services
April 6, 2021

Literature on pediatric mental health has suggested that adverse children’s experiences have been widespread and have gone unaddressed or untreated. A recent cross-sectional study was conducted to estimate the proportion of children with high levels of adverse children’s experiences or mental health symptoms who have not been receiving services from behavioral health professionals...

Continue reading (Members only)

FDA Approves New Treatment For ADHD In Pediatric Patients
April 2, 2021

A U.S. Food and Drug Administration approves viloxazine extended-release capsules for the treatment of attention-deficit hyperactivity disorder in pediatric patients 6 to 17 years of age...

Studies Show Increased Risk of Heart Rhythm Problems in Patients Taking Lamotrigine
April 1, 2021

A U.S. Food and Drug Administration review of study findings showed a potential increased risk of arrhythmias in patients with heart disease who are taking the seizure and mental health medicine lamotrigine....

Continue reading (Members only)

PsychopharmaStahlogy Show: Psychedelic Assisted Psychotherapy
March 30, 2021

The PsychopharmaStahlogy Show is a special podcast series released on the NEI Podcast. In the first three part series, Dr. Andrew Cutler asks Dr. Stephen Stahl important questions relating to psychedelic assisted psychotherapy as a novel approach to the treatment of psychiatric disorders...

Psychotropic Polypharmacy Prevalent in Patients With Dementia
March 25, 2021

Dementia is increasingly prevalent as the population ages. In addition to memory deficits, patients with dementia often exhibit other neuropsychiatric symptoms that can be disturbing to caregivers and increase the likelihood of institutionalization. It is therefore not uncommon for patients with dementia to be prescribed psychotropic agents despite...

Continue reading (Members only)

Ketamine for Adolescents With Treatment-Resistant Depression
March 23, 2021

The glutamatergic agent, ketamine, has been increasingly studied and shown to have great benefit in adults with major depressive disorder but has not been as thoroughly examined in children and adolescents. In this study...

Continue reading (Members only)

Happy Match Day 2021!
March 19, 2021

Congratulations to all of the medical students who have found a match for their psychiatry residency program! Diversity, Equity, and Inclusion (DEI) in academic psychiatry is of utmost importance, and DEI Leadership at major academic psychiatry programs across the United States have outlined a roadmap of guidelines for success...

Top of Page